- About Us
- Advisory Board
- Editorial
- Contact Us
- Advertise
- Contact MJH LS
- Do Not Sell My Information
- Terms and Conditions
- Privacy
© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.
Multiple Sclerosis
The NeurologyLive multiple sclerosis (MS) clinical focus page offers information, podcasts, videos, and news about the latest study and clinical trial findings, FDA actions, clinical guideline updates, and expert interviews related to the care and management of patients with MS, including relapsing MS and progressive MS, as well as related disorders such as neuromyelitis optica spectrum disorder.
Verdiperstat Fails ALS Study, Lecanemab Shines in Latest Phase 3 Findings, Ofatumumab Continues Superiority Over Teriflunomide
October 01, 2022
Video
Neurology News Network for the week ending October 1, 2022. [WATCH TIME: 4 minutes]
NeurologyLive® Friday 5 — September 30, 2022
September 30, 2022
Article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 23, 2022.
Aerobic Exercise for MS Positively Affects Motor-related Tract and Nuclei Microstructural Integrity
September 28, 2022
Article
Although data from the EMSES study failed to reveal a reduction in relapse rates or global brain atrophy, half of the important motor-related tracts and nuclei observed displayed higher structural integrity in exercise patients.
Ofatumumab Outperforms Teriflunomide in Newly Diagnosed, Treatment-Naïve Multiple Sclerosis
September 28, 2022
Article
Consistent with the overall population, newly diagnosed, treatment-naïve patients with MS showed better relapse rates, all-cause disability worsening—including progression independent of relapse activity—with ofatumumab over teriflunomide.
Long-Term Safety of MS Treatment Ofatumumab Confirmed in ALITHIOS Extension
September 27, 2022
Article
Over a 3.5-year treatment period, the risk of serious infections or malignancies, few of which were previously reported, did not increase with additional ofatumumab exposure.
Dimethyl Fumarate Shows Low MS Relapse Rates, Encouraging Safety After 13-Year Analysis
September 26, 2022
Article
Over a long-term follow-up, a high proportion of patients were compliant to therapy, with adverse events mild-to-moderate in nature, regardless of individuals being on continuous treatment or switched from placebo.
The Future of Multiple Sclerosis Treatment
September 26, 2022
Video
Ahmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, share their hopes about the evolution of future mutiple sclerosis care and express their gratitude for the next generation of neurologists.
Novel Mechanisms of Action for Multiple Sclerosis Treatment
September 26, 2022
Video
Drs Hesham Abboud and Benjamin Greenberg share their excitement for the future of multiple scelrosis treatment and comment on emerging therapies and novel mechanisms of action.
Future Thoughts on BTK Inhibitors in Multiple Sclerosis
September 26, 2022
Video
Ahmed Obeidat, MD, PhD; Benjamin Greenberg, MD; and Hesham Abboud, MD, discuss their future hopes and concerns for the use of BTK inhibitors in the treatment of multiple sclerosis.
This Week on NeurologyLive® — September 26, 2022
September 26, 2022
Article
Here's some of what is coming soon to NeurologyLive® this week.
Latest News
Verdiperstat Fails ALS Study, Lecanemab Shines in Latest Phase 3 Findings, Ofatumumab Continues Superiority Over Teriflunomide
Night-Time Only Apomorphine Infusion Shows Benefit to Treating Parkinson Disease Insomnia
NeurologyLive® Friday 5 — September 30, 2022
Electroacupuncture for Insomnia Significantly Improves Quality of Sleep in Patients With Depression